Nothing Special   »   [go: up one dir, main page]

WO2004076615A3 - Immunomodulating probiotic compounds - Google Patents

Immunomodulating probiotic compounds Download PDF

Info

Publication number
WO2004076615A3
WO2004076615A3 PCT/DK2004/000138 DK2004000138W WO2004076615A3 WO 2004076615 A3 WO2004076615 A3 WO 2004076615A3 DK 2004000138 W DK2004000138 W DK 2004000138W WO 2004076615 A3 WO2004076615 A3 WO 2004076615A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
intracellular
bifidobacterium
lactobacillus
polypeptides
Prior art date
Application number
PCT/DK2004/000138
Other languages
French (fr)
Other versions
WO2004076615A9 (en
WO2004076615A2 (en
Inventor
Hans Israelsen
Soeren Michael Madsen
Jacob Glenting
Astrid Vrang
Mette Rindom Noerrelykke
Anne Maria Hansen
Siv Elsa Ingegerd Ahrne
Goeran Molin
Peter Ravn
Hans Christian Beck
Original Assignee
Bioneer As
Probi Ab
Hans Israelsen
Soeren Michael Madsen
Jacob Glenting
Astrid Vrang
Mette Rindom Noerrelykke
Anne Maria Hansen
Siv Elsa Ingegerd Ahrne
Goeran Molin
Peter Ravn
Hans Christian Beck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer As, Probi Ab, Hans Israelsen, Soeren Michael Madsen, Jacob Glenting, Astrid Vrang, Mette Rindom Noerrelykke, Anne Maria Hansen, Siv Elsa Ingegerd Ahrne, Goeran Molin, Peter Ravn, Hans Christian Beck filed Critical Bioneer As
Publication of WO2004076615A2 publication Critical patent/WO2004076615A2/en
Publication of WO2004076615A9 publication Critical patent/WO2004076615A9/en
Publication of WO2004076615A3 publication Critical patent/WO2004076615A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01012—Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (1.2.1.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0067—Oxidoreductases (1.) acting on hydrogen as donor (1.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1217—Phosphotransferases with a carboxyl group as acceptor (2.7.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/02—Phosphotransferases with a carboxy group as acceptor (2.7.2)
    • C12Y207/02003—Phosphoglycerate kinase (2.7.2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/01—Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)
    • C12Y503/01001—Triose-phosphate isomerase (5.3.1.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods for modulating i) an immune response and/or ii) the amount and/or composition of mucosal mucins, by contacting a cell forming part of mucosal­associated lymphoid tissue (MALT), or an epithelial cell, with a microbial cell surface polypeptide. The modulation of the immune response preferably involves the induction of one or more cytokines. The microbial cell surface polypeptide is preferably a polypeptide obtained from probiotic species of Lactobacillus or Bifidobacterium. It has surprisingly been found that intracellular enzymes acting in metabolic pathways in Lactobacillus and Bifidobacterium, or polypeptides substantially identical with such intracellular enzymes, are transported to the surface of the cell where they may become at least partially exposed to the extracellular medium. Accordingly, preferred cell surface polypeptides have intracellular (i.e. cytoplasm associated) equivalents acting in metabolic pathways, such as e.g. glycolysis, in probiotic species of Lactobacillus and/or Bifidobacterium. The surface associated polypeptides and their intracellular equivalents share an extended stretch of consecutive amino acid residues, but are located in different parts of a cell.
PCT/DK2004/000138 2003-02-27 2004-02-27 Immunomodulating probiotic compounds WO2004076615A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44984003P 2003-02-27 2003-02-27
US60/449,840 2003-02-27
DKPA200300315 2003-02-27
DKPA200300315 2003-02-27
US48215603P 2003-06-25 2003-06-25
US60/482,156 2003-06-25

Publications (3)

Publication Number Publication Date
WO2004076615A2 WO2004076615A2 (en) 2004-09-10
WO2004076615A9 WO2004076615A9 (en) 2004-10-14
WO2004076615A3 true WO2004076615A3 (en) 2004-12-09

Family

ID=32930957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000138 WO2004076615A2 (en) 2003-02-27 2004-02-27 Immunomodulating probiotic compounds

Country Status (1)

Country Link
WO (1) WO2004076615A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070089231A (en) * 2004-12-14 2007-08-30 알크-아벨로 에이/에스 Pharmaceutical composition comprising a bacterial cell displaying a heterologous proteinaceous compound
TW200700074A (en) 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
HUE030542T2 (en) * 2005-10-06 2017-05-29 Probi Ab Use of lactobacillus for treatment of virus infections
MX2009006887A (en) * 2006-12-21 2009-08-27 Calpis Co Ltd IgA PRODUCTION PROMOTER.
RU2466185C2 (en) 2007-03-28 2012-11-10 Элиментари Хелт Лимитед PROBIOTIC STRAIN Bifidobacterium longum, PROBIOTIC COMPOSITION AND USE OF STRAIN Bifidobacterium longum
DK2134833T3 (en) 2007-03-28 2016-06-20 Alimentary Health Ltd Probiotic Bifidobacterium strain
FR2922450B1 (en) * 2007-10-19 2014-06-13 Lallemand Sas USE OF LACTIC ACID BACTERIA FOR THE PREVENTION AND / OR TREATMENT OF SKIN CONDITIONS
ES2343499B1 (en) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas MICROORGANISMS TO IMPROVE THE STATE OF HEALTH OF INDIVIDUALS WITH DISORDERS RELATED TO THE INTAKE OF GLUTEN.
EE05341B1 (en) * 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Isolated microorganism or Lactobacillus plantarum Inducia DSM 21379 as a probiotic that enhances the natural defenses of the organism, the food and the composition containing them, and the use of the microorganism in the preparation of a cell-mediated immunity
WO2010096550A2 (en) * 2009-02-18 2010-08-26 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
JP5468183B2 (en) * 2011-12-28 2014-04-09 株式会社山田養蜂場本社 Novel lactic acid bacteria having IgA production promoting action and use thereof
WO2015121458A2 (en) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprising bifidobacterium animalis ssp. lactis
MX2018002533A (en) 2015-09-29 2018-06-27 Kimberly Clark Co Synergistic composition for maintenance of healthy balance of microflora.
BR112019014418A2 (en) * 2017-01-12 2020-04-14 Probi Ab probiotic compositions and uses thereof
BR112019015239A2 (en) 2017-02-28 2020-04-14 Kimberly Clark Co composition, and, method to maintain a healthy microflora balance in the urogenital area of a patient in need of it.
EP3600365A4 (en) 2017-03-29 2021-01-06 President and Fellows of Harvard College Methods of regulating gene expression in a cell
EP3905893A4 (en) * 2019-01-06 2022-04-27 Second Genome, Inc. Microbially derived peptides and proteins for immunotherapy
CN110144311B (en) * 2019-05-21 2022-07-01 黑龙江大学 Lactobacillus kefir and bacterial preparation thereof
CN110184214B (en) * 2019-05-21 2022-07-01 黑龙江大学 Lactobacillus kefir and bacterial preparation thereof
CN112501049B (en) * 2020-10-28 2022-04-19 石河子大学 Lactobacillus kefir producing transglycosylation active beta-galactosidase and method for producing galactooligosaccharides by using prepared beta-galactosidase
CN114381411B (en) * 2022-03-23 2022-05-27 山东中科嘉亿生物工程有限公司 Lactococcus lactis JYLL-60 and application thereof in preparation of product for improving immunity
CN116445321B (en) * 2022-12-13 2023-11-24 广西爱生生命科技有限公司 Lactobacillus reuteri A21160 capable of lowering nucleoside and blood uric acid and application thereof
CN116694530B (en) * 2023-06-28 2023-11-07 北京量化健康科技有限公司 Lactobacillus composition and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012506A1 (en) * 2000-08-08 2002-02-14 Genesis Research And Development Corporation Limited Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012506A1 (en) * 2000-08-08 2002-02-14 Genesis Research And Development Corporation Limited Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BORRUEL N ET AL: "INCREASED MUCOSAL TUMOUR NECROSIS FACTOR ALPHA PRODUCTION IN CROHN'S DISEASE CAN BE DOWNREGULATED EX VIVO BY PROBIOTIC BACTERIA", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 51, 2002, pages 659 - 664, XP008023641, ISSN: 0017-5749 *
DATABASE EMBL [online] 6 February 2003 (2003-02-06), KLEEREBEZEM M ET AL: "Lactobacillus plantarum strain WCFS1 complete genome; segment 3/11", XP002298978, retrieved from EBI Database accession no. AL935254 *
HUGHES M J G ET AL: "Identification of major outer surface proteins of Streptococcus agalactiae", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 70, no. 3, March 2002 (2002-03-01), pages 1254 - 1259, XP002254598, ISSN: 0019-9567 *
KLEEREBEZEM MICHIEL ET AL: "Complete genome sequence of Lactobacillus plantarum WCFS1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 100, no. 4, 18 February 2003 (2003-02-18), pages 1990 - 1995, XP002285325, ISSN: 0027-8424 *
PANCHOLI V: "Multifunctional alpha-enolase: Its role in diseases", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 58, no. 7, June 2001 (2001-06-01), pages 902 - 920, XP002288673, ISSN: 1420-682X *
ULRICH R L ET AL: "Cloning and expression analysis of the 28 kDa protein from Lactobacillus delbrueckii subsp. lactis ATCC 4797 hypothesized to influence lactacin B production", JOURNAL OF APPLIED MICROBIOLOGY, vol. 91, no. 6, December 2001 (2001-12-01), pages 1067 - 1073, XP002288674, ISSN: 1364-5072 *

Also Published As

Publication number Publication date
WO2004076615A9 (en) 2004-10-14
WO2004076615A2 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
WO2004076615A3 (en) Immunomodulating probiotic compounds
Singh et al. Growth and bioactive peptides production potential of Lactobacillus plantarum strain C2 in soy milk: A LC-MS/MS based revelation for peptides biofunctionality
Li et al. Purification and identification of novel peptides with inhibitory effect against angiotensin I-converting enzyme and optimization of process conditions in milk fermented with the yeast Kluyveromyces marxianus
Yang et al. Amino acid composition, molecular weight distribution and antioxidant activity of protein hydrolysates of soy sauce lees
Nongonierma et al. Quinoa (Chenopodium quinoa Willd.) protein hydrolysates with in vitro dipeptidyl peptidase IV (DPP-IV) inhibitory and antioxidant properties
Brandelli et al. Whey as a source of peptides with remarkable biological activities
Sanchez-Rivera et al. Bioavailability and kinetics of the antihypertensive casein-derived peptide HLPLP in rats
Zhao et al. Synthesis of taste-active γ-glutamyl dipeptides during sourdough fermentation by Lactobacillus reuteri
Hernández-Ledesma et al. Application of high-performance liquid chromatography–tandem mass spectrometry to the identification of biologically active peptides produced by milk fermentation and simulated gastrointestinal digestion
MX2010014091A (en) Protein hydrolysate compositions stable under acidic conditions.
IN2014CN02050A (en)
Chanalia et al. Extraction, purification and characterization of low molecular weight Proline iminopeptidase from probiotic L. plantarum for meat tenderization
EP0786473A3 (en) Basic protein composition, basic peptide composition and application thereof
Zhao et al. Preparation and radical scavenging activity of papain-catalyzed casein plasteins
CO2022006972A2 (en) Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins
MY159532A (en) Seasoning products with high content of sweet amino acids and yeast strain for use in obtaining the same
JPH05505524A (en) protein hydrolyzate
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
Meshginfar et al. Physicochemical, antioxidant, calcium binding, and angiotensin converting enzyme inhibitory properties of hydrolyzed tomato seed proteins
US10604780B2 (en) Low gluten yeast hydrolysates
CA2838262C (en) Methods of phosvitin extraction and phosphopeptide preparation from egg yolk
DE502006008613D1 (en) Process for the fermentative production of proteins
Gong et al. Investigation of nutritional and functional effects of rice bran protein hydrolysates by using Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines: A review
Inoue et al. Release of antihypertensive peptides in miso paste during its fermentation, by the addition of casein
Gao et al. Characterization and formation mechanism of proteins in the secondary precipitate of soy sauce

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: SEQUENCE LISTING, ADDED, (1-27 PAGES)

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase